Feline Histoplasmosis

Feline histoplasmosis is a systemic fungal infection caused by Histoplasma capsulatum, a dimorphic fungus with worldwide distribution that is endemic in 31 of the 48 contiguous United States [1]. It represents the second most commonly reported fungal infection in cats, after cryptococcosis [1]. The organism primarily enters the host through inhalation of aerosolized microconidia from contaminated soil, with potential additional entry via ingestion [1]. Once inhaled, the fungus is capable of disseminating widely through the bloodstream and lymphatic system, involving multiple organ systems and making feline histoplasmosis a potentially life-threatening disease [1][3].

Histoplasma capsulatum is a thermally dimorphic fungus that exists as a saprophytic mold in the environment and converts to a pathogenic yeast form at body temperature [1]. The organism thrives in moist, nitrogen-rich soils, particularly those contaminated with bat or bird droppings, and is endemic across the Ohio, Mississippi, and Missouri River valleys in North America, as well as having a broader worldwide distribution [1][4].

Route of infection: Infection most commonly occurs via inhalation of microconidia or mycelial fragments from disturbed soil. Ingestion has also been proposed as a potential route of entry in cats [1]. Because spores are airborne, indoor cats may also be susceptible to infection [3].

Pathogenesis: Once the microconidia are inhaled and deposited in the lower respiratory tract, they undergo thermal conversion to the yeast phase. The yeast cells are phagocytized by alveolar macrophages; however, the organism is capable of surviving and replicating within these macrophages. This intracellular parasitism enables H. capsulatum to evade the host's initial immune defenses [1]. Infected macrophages then disseminate the organism hematogenously and via the lymphatics to the reticuloendothelial system, gastrointestinal tract, liver, spleen, bone marrow, eyes, skin, and other organs [1][3]. In immunocompetent hosts, cell-mediated immunity (CMI) may contain the infection, leading to granuloma formation and subclinical disease. However, when CMI is impaired or overwhelmed — as may occur with a high fungal burden, concurrent immunosuppression, or retroviral infection (e.g., FeLV or FIV) — progressive disseminated histoplasmosis develops [1][3]. The widespread granulomatous inflammation and direct tissue invasion underlie the diverse and multi-systemic clinical presentation observed in affected cats [1].

Diagnosis of feline histoplasmosis requires integration of clinical findings, laboratory data, cytology or histopathology, and — when available — fungal culture or antigen testing [1][3].

Clinicopathological Laboratory Findings

Routine bloodwork often reveals characteristic, though non-specific, abnormalities:

• ·

  Complete Blood Count (CBC):

  • ·Anemia (low HCT/PCV): Normocytic, normochromic non-regenerative anemia is common, reflecting bone marrow infiltration or anemia of chronic disease [1]
  • ·Leukopenia or leukocytosis (low or high WBC): Variable; leukopenia may occur with bone marrow suppression, while leukocytosis may reflect secondary inflammation [1]
  • ·Thrombocytopenia (low PLT): May result from bone marrow involvement [1]
  • ·Occasionally, intracellular yeast organisms may be observed directly within circulating monocytes or neutrophils on blood smear examination — a highly specific finding when present [1][3]
• ·

  Serum Biochemistry:

  • ·Hypoalbuminemia (low ALB): Frequently noted, reflecting protein-losing enteropathy, liver dysfunction, or chronic disease [1][6]
  • ·Hyperglobulinemia (high GLOB): Polyclonal gammopathy consistent with chronic antigenic stimulation [1]
  • ·Elevated liver enzymes (high ALT, ALP): Reflect hepatic infiltration with the organism [1]
  • ·Elevated bilirubin (high TBIL): Possible with significant hepatic involvement [1]
  • ·Azotemia (elevated BUN/CREA): May occur if renal involvement is present, though less common [1]
• ·

  Thoracic radiography: Pulmonary involvement may manifest as a diffuse interstitial or miliary nodular pattern, bronchopneumonia, or hilar lymphadenopathy [2]. These findings are consistent with mycotic pneumonia and should raise clinical suspicion for systemic fungal infection in endemic areas [2].

• ·

  Cytology and Histopathology: Definitive diagnosis most commonly relies on cytological identification of the small (2–4 µm), intracellular, oval yeast organisms within macrophages [1][3]. Samples may be obtained from:

  • ·Fine-needle aspirates of lymph nodes, liver, spleen, or cutaneous lesions
  • ·Bronchoalveolar lavage (BAL) or tracheal wash
  • ·Bone marrow aspirate
  • ·Rectal scraping in cases with GI involvement
  • ·Histopathological examination of biopsy specimens with PAS or GMS staining [3]
• ·

  Fungal culture: Although confirmatory, culture is slow (weeks), poses a biosafety risk (Biosafety Level 3 pathogen), and is not routinely performed in clinical practice [1][3].

• ·

  Antigen detection (urine/serum EIA): Histoplasma antigen ELISA testing of urine or serum (using assays validated in humans, such as MiraVista®) has been employed in cats and can support diagnosis, particularly when cytology is unrewarding [3]. Cross-reactivity with other fungi (e.g., Blastomyces) should be noted [3].

• ·

  Serology: Agar gel immunodiffusion (AGID) and complement fixation tests are available but have limited sensitivity and specificity in cats, and false-negative results are common in immunocompromised animals [1].

Long treatment durations are typically required for feline histoplasmosis, and even after clinical cure is achieved, the risk of relapse exists [5]. Owner compliance and patient tolerance of prolonged antifungal therapy are important practical considerations [5].

Itraconazole (first-line therapy)

Itraconazole is the treatment of choice for feline histoplasmosis in most cases [1][5]. The recommended dosage in cats is typically 5–10 mg/kg orally once daily or divided twice daily. The lipid-based oral solution formulation may improve bioavailability compared to capsules [5]. Treatment should be continued for a minimum of 4–6 months, and therapy should not be discontinued until the patient has been clinically normal for at least 1–2 months [1][5]. Regular monitoring of liver enzymes (ALT, ALP) is recommended during treatment, as hepatotoxicity is a recognized adverse effect [5].

Fluconazole

Fluconazole may be used as an alternative to itraconazole, particularly given its superior CNS and ocular penetration, making it preferable when neurological or ocular involvement is documented [1][5]. It is generally well tolerated in cats.

Posaconazole

Posaconazole represents a newer triazole option with activity against H. capsulatum. Its use in feline histoplasmosis was first reported in a case of disseminated disease refractory to itraconazole [6]. In that case, the cat was transitioned to posaconazole and subsequently maintained on a combination of itraconazole and terbinafine, ultimately achieving clinical remission [6]. This case supports the potential utility of posaconazole in refractory or severe cases, though clinical data in cats remain limited [6].

Combination Therapy

The combination of itraconazole and terbinafine has been reported as a salvage strategy in a cat with disseminated histoplasmosis refractory to monotherapy, resulting in long-term clinical remission [6]. This approach may be considered in cases where single-agent therapy fails [6].

Amphotericin B

Amphotericin B (lipid complex or deoxycholate formulation) may be used in severe, rapidly progressive, or life-threatening disseminated disease [1][5]. Due to its nephrotoxic potential, renal function (BUN, CREA) should be closely monitored during administration; the lipid complex formulation is preferred in cats to reduce nephrotoxicity [5].

Supportive Care

Supportive care is an essential component of management and may include:

• ·Nutritional support (assisted feeding, appetite stimulants) for anorexic and cachectic patients [1]
• ·IV fluid therapy to maintain hydration and support renal function [1]
• ·Treatment of anemia if severe (blood transfusion in life-threatening cases)
• ·Ophthalmic medications for uveitis or ocular involvement

Monitoring

Response to therapy should be assessed every 4–6 weeks using clinical examination, body weight, CBC, serum biochemistry, and thoracic radiography where applicable [1][5]. Antigen titers, where available, can be used to monitor treatment response and detect relapse [3][5].

The prognosis for feline histoplasmosis is variable and depends heavily on the extent of dissemination, the organs involved, and the patient's immune status at the time of diagnosis [1][3].

General prognosis: Cats with pulmonary or localized disease that are diagnosed early and treated appropriately with antifungal therapy generally have a favorable prognosis [1]. However, disseminated disease — particularly cases involving the bone marrow, gastrointestinal tract, liver, or eyes — carries a more guarded to poor prognosis [1][3].

Response to therapy: Many cats show improvement with prolonged itraconazole therapy, but relapses can occur after discontinuation of treatment, and lifelong antifungal therapy may occasionally be required in immunocompromised individuals [1][5]. The case report by Farber-Klein et al. (2024) demonstrates that clinical remission can be achieved even in refractory disseminated cases with escalated or combination therapy, though the clinical course may be prolonged and complicated [6].

Refractory disease: Cases refractory to standard itraconazole therapy carry a guarded prognosis, though emerging evidence suggests that posaconazole and combination regimens (e.g., itraconazole plus terbinafine) may offer salvage options [6].

Quantitative survival statistics: The current veterinary literature cited does not provide explicit case-fatality rates or formal survival statistics specific to cats with histoplasmosis. The prognosis statements above are based on clinical outcome descriptions and expert consensus within the referenced sources [1][3][5][6]. Prospective survival studies in feline patients are lacking, representing a gap in the current literature.

There is no approved vaccine for Histoplasma capsulatum in cats [3]. Prevention therefore relies primarily on reducing environmental exposure and maintaining the overall health of susceptible animals.

Environmental exposure reduction:

• ·Avoid allowing cats to roam in or excavate areas with high-risk soil, such as sites contaminated with bird or bat droppings (e.g., old barns, chicken coops, cave entrances, riverbanks) in endemic regions [1][4]
• ·Minimizing outdoor access in highly endemic areas may reduce infection risk, though it is important to recognize that indoor cats can also be exposed to airborne spores and are not completely protected [3]

Immune health:

• ·Routine screening and management of concurrent immunosuppressive diseases (e.g., FeLV, FIV, or iatrogenic immunosuppression from long-term corticosteroids) may reduce the risk of severe or disseminated infection [1][3]
• ·Maintaining good nutritional status and overall wellness supports competent cell-mediated immune responses that are critical for containment of H. capsulatum [1]

Zoonotic awareness:

• ·Cats with histoplasmosis do not directly transmit the infection to humans through contact, as transmission requires inhalation of the environmental mold phase [4]. However, H. capsulatum is classified as a zoonotic pathogen via soil exposure, and veterinary staff handling culture specimens or heavily infected tissues should exercise appropriate biosafety precautions [4][3]
• ·Immunocompromised owners should be made aware of the shared environmental risk and advised to consult their physician [4]